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Abstract The brain-derived neurotrophic factor (BDNF)
is a key regulator of synaptic plasticity and has been sug-
gested to be involved in the pathophysiology and patho-
genesis of psychotic disorders, with particular emphasis on
dysfunctions of the hippocampus. The aim of the present
study was to replicate and to extend prior ﬁndings of
BDNF val66met genotype effects on hippocampal volume
and N-acetyl aspartate (NAA) levels. Hundred and ﬁfty-
eight caucasians (66 schizophrenic, 45 bipolar, and 47
healthy subjects; 105 subjects underwent MRI and 103
MRS scanning) participated in the study and were geno-
typed with regard to the val66met polymorphism (rs6265)
of the BDNF gene. Hippocampal volumes were determined
using structural magnetic resonance imaging (MRI), and
measures of biochemical markers were taken using pro-
ton magnetic resonance spectroscopy (
1H-MRS) in the
hippocampus and other brain regions. Verbal memory was
assessed as a behavioral index of hippocampal function.
BDNF genotype did not impact hippocampal volumes.
Signiﬁcant genotype effects were found on metabolic
markers speciﬁcally in the left hippocampus. In particular,
homozygous carriers of the met-allele exhibited signiﬁ-
cantly lower NAA/Cre and (Glu ? Gln)/Cre metabolic
ratios compared with val/val homozygotes, independently
of psychiatric diagnoses. BDNF genotype had a numerical,
but nonsigniﬁcant effect on verbal memory performance.
These ﬁndings provide ﬁrst in vivo evidence for an effect
of the functional BDNF val66met polymorphism on the
glutamate system in human hippocampus.
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Introduction
Brain-derived neurotrophic factor (BDNF) modulates hip-
pocampal plasticity, hippocampal-dependent memory and
has been suggested to be involved in the pathophysiology
of different mental disorders [10, 17, 43]. In particular, a
close relationship appears to exist between BDNF and
schizophrenia [27] and affective disorders [40], implicating
that BDNF may be a candidate gene for these mental dis-
orders. BDNF acts as a vital trophic protein for neuronal
survival and differentiation in the developing nervous
system [22] and modulates cholinergic, dopaminergic, and
serotonergic neurons, which may also have an impact on
the etiopathogenesis of mental disorders [13, 38, 41].
Recent studies revealed an important role of BDNF in the
regulation of glutamatergic synapses and glutamate
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DOI 10.1007/s00406-011-0214-6receptor activity [6], which may represent one important
link between BDNF and hippocampal function. Glutamate
receptor function is essential for memory functions, and the
hippocampal pyramidal layers are densely packed with
glutamate-containing excitatory neurons. These neurons
are involved in the induction of long-term potentiation
(LTP) and long-term depression (LTD), which are the
cellular and molecular mechanisms underlying memory
[29, 42].
The gene encoding human BDNF is localized to chro-
mosome 11, band p13 and it encodes a precursor peptide
(proBDNF), which is cleaved to form the mature protein
via proteolyses [10, 28]. It was shown that the frequent
nonconservative amino acid substitution valine to methio-
nine on codon 66 (val66met—polymorphism, dbSNP
number rs6265) in the 50 signal domain of BDNF gene
leads to disturbances in the intracellular packaging and
regulated secretion of BDNF without affecting mature
BDNF protein function [10]. In normal individuals, this
frequent polymorphism (met-allele carriers) has been
shown to affect human hippocampal function, episodic
memory, and declarative memory [7, 10, 17, 19]. In par-
ticular, previous studies revealed smaller hippocampal
volume in met-allele carriers independent of age and
gender in healthy subjects [5, 37]. Studies using magnetic
resonance spectroscopic imaging (MRS) reported an
association between the functional BDNF val66met poly-
morphism and reduced hippocampal N-acetyl aspartate
(NAA) [10, 41].
The aims of the present study were, ﬁrst, to replicate and
extend prior ﬁndings of BDNF effects on hippocampal
volume [5, 37] and NAA [10, 41] by assessing the effect of
the BDNF val66met polymorphism in a large and ethni-
cally homogeneous sample including healthy individuals
and psychiatric patients suffering from psychotic disorders
(schizophrenia and bipolar affective disorder, heteroge-
neous clinical status). Second, we sought to provide
empirical evidence for the hypothesis that the BDNF
val66met polymorphism may also impact on glutamatergic
mechanisms in the human hippocampus [6, 41]. For these
purposes, we determined hippocampal brain volumes using
structural magnetic resonance imaging (MRI) and per-
formed in vivo measures of hippocampal NAA, choline,
creatine, and glutamate/glutamine using proton magnetic
resonance spectroscopy (
1H-MRS). Furthermore, in order
to address memory indices of hippocampal function, sub-
jects were tested with the verbal learning memory test
(VLMT, [35]). Based on the results of prior studies, we
hypothesized that carriers of the met-allele (val/met, met/
met genotype) would reveal lower N-acetyl aspartate and
glutamate levels, lower hippocampal gray matter volume,
and worse memory performance in the VLMT than val/val
homozygotes.
Materials and methods
Subjects
Sixty-six patients suffering from schizophrenia (SZ), 45
patients with bipolar I disorder (BP), and 47 healthy
controls participated in the study. All subjects were
recruited from the Saarland area, and all of them were
Caucasians of European ancestry (most German). A
subsample of these subjects underwent MRI (n = 105) or
MRS (n = 103) scanning. All patients provided informed
consent before entering the study, and the study design
was approved by the local ethics committee. Diagnoses
were based on the German version of the Structural
Clinical Interview for DSM IV [44] and were consented
within members of the study group and the treating
clinical psychiatrist, who was blind to the aims of the
study. Patients were excluded from the study if they met
a n yo ft h ef o l l o w i n gc r i t e r i a: organic central nervous
system disorder (e.g., epilepsy, traumatic brain injury,
infectious, toxic, or cerebrovascular disease), mental
retardation, or inadequate knowledge of the German
language. At the time of the study, most patients received,
depending on the disease, a stable medication, including
typical and atypical neuroleptics, mood stabilizers, and
benzodiazepines. Healthy control subjects exhibited no
past or present psychiatric, neurological or medical dis-
order and had no positive family history of psychiatric
d i s o r d e r s .D e m o g r a p h i cd a t af o rt h es t u d ys a m p l ea r e
given in Table 1. Clinical characteristics and psycho-
pathological scores for the patient groups are presented in
Table 2.
MRI acquisition and volumetric measurement
MRI scanning was performed on a 1.5-Tesla Magnetom
Sonata (Siemens, Erlangen). A T1-weighted, magnetization
prepared rapid gradient echo sequence (MPRAGE)
(echo time, TE = 4 ms; repetition time, TR = 1.900 ms;
inversion time, TI = 700 ms, ﬂip angle = 15, image
matrix = 256 9 256 mm) generating 176 consecutive
sagittal slices with a voxel size of 1 mm
3 was acquired.
Image processing and analysis used the software packages
Analyze (Mayo Foundation, 1999), Statistical Parametric
Mapping (SPM99, Institute of Neurology, London, UK,
[2], exclusively used in order to determine total gray matter
volume) as well as interactive data language applications
(IDL) generated in our imaging lab. First, the MR images
were realigned in parallel to the AC–PC (anterior com-
missure and posterior commissure) plane. As described
previously [14], hippocampal morphometry in all partici-
pants was conducted manually by raters (hand tracing) who
were blind to diagnosis and genotype. Hippocampal
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123contours were drawn in the sagittal view using the ‘‘region
of interest’’ tool implemented in the software Analyze.
After having completed the drawing for all sagittal slices in
which the hippocampus was visible, the correctness of the
contours was controlled in the coronal and horizontal
views. Subsequently, both the hippocampal volumes as
marked by the two-dimensional drawings and the total
brain volumes were determined using an automatic algo-
rithm programmed in MATLAB and SPM99. Because we
were interested in speciﬁc effects on the size of the hip-
pocampus independent from total brain volumes, statistical
analysis was performed on relative hippocampal volumes
expressed by the quotient of hippocampal and total brain
volume.
Proton magnetic resonance spectroscopy
As described previously [39], single-volume
1H-MRS was
performed on a 1.5-Tesla Siemens Magnetom Sonata
(Siemens, Erlangen) using a spin-echo sequence with
water suppression and 128 scan averages (TE = 30,
TR = 1.500). Regions of interest were deﬁned in the left
hippocampus, in the middle third of the left middle frontal
gyrus (referred to as left dorsolateral prefrontal cortex), and
in the left posterior frontomedian cortex along the cingulate
sulcus. These regions were determined according to an
exactly predeﬁned and standardized algorithm with multi-
ple rechecking procedures in a T2 gradient echo image
(TrueFISP) with 24 slices each in three orthogonal orien-
tations. The positions of the voxels were visually inspected
and adjusted based on identiﬁable anatomical landmarks in
reference to standard brain atlases. The voxel sizes were
adjusted to the morphology of the anatomical target
structures and were 10 9 35 9 10 mm
3 for the hippo-
campus (see Fig. 1) and the middle third of the middle
frontal gyrus, and 12 9 20 9 15 mm
3 for the posterior
frontomedian cortex.
All spectra were postprocessed by using the Siemens
Medical Solutions spectroscopy software package on a
Leonardo workstation. Following acquisition, low-frequency
Table 1 Demographic and clinical data of study subjects
Variable Val/val Val/met Met/met Statistic P
All subjects
N 94 56 8
Gender 39 M, 55 F 36 M, 20 F 6 M, 2 F v
2(2) = 9.2 0.01
Age (years; ± SD) 37.6 ± 11.7 38.8 ± 13.3 39.5 ± 14.7 F(2, 155) = 0.2 0.81
Education (years; ± SD) 13.7 ± 3.0 13.6 ± 2.9 14.0 ± 3.5 F(2, 155) = 0.1 0.95
Diagnosis: control subjects (N)2 7 1 6 4 v
2(4) = 3.2 0.52
Diagnosis: schizophrenia (N)4 3 2 1 2
Diagnosis: bipolar disorder (N)2 4 1 9 2
Subjects with hippocampal MRI data
N 60 41 4
Gender 26 M, 34 F 28 M, 13 F 2 M, 2 F v
2(2) = 6.1 0.047
Age (yrs; ± SD) 38.03 ± 12.1 37.82 ± 13.8 48.53 ± 13.0 F(2, 102) = 1.3 0.28
Education (years; ± SD) 13.84 ± 2.97 13.78 ± 2.8 15.25 ± 3.2 F(2, 102) = 0.5 0.62
Diagnosis: control subjects (N)2 4 1 2 3 v
2(4) = 5.48 0.24
Diagnosis: schizophrenia (N)2 0 1 2 0
Diagnosis: bipolar disorder (N)1 6 1 7 1
Subjects with hippocampal MRS data
N 61 38 4
Gender 28 M, 33 F 28 M, 10 F 2 M, 2 F v
2(2) = 7.4 0.025
Age (years; ± SD) 38.22 ± 12.3 37.48 ± 13.6 48.53 ± 13.1 F(2, 100) = 1.35 0.26
Education (years; ± SD) 13.74 ± 2.86 13.97 ± 2.71 15.25 ± 3.2 F(2, 100) = 0.57 0.57
Diagnosis: control subjects (N)2 3 1 1 3 v
2(4) = 4.62 0.33
Diagnosis: schizophrenia (N)2 2 1 3 0
Diagnosis: bipolar disorder (N)1 6 1 4 1
Data are presented as mean ± standard deviation unless otherwise indicated. Values are expressed as v
2 statistics for categorical variables and
F statistics for continuous variables. conv. conventional, F female, N number, M male, and SD standard deviation
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123ﬁltering for removal of the residual water signal and
correction for frequency shifts were performed. Data were
zero-ﬁlled from 1.024 to 2.048 points. After apodization
of the time domain signal by a Hanning function with
700 ms width, the data were Fourier transformed to the
frequency domain. The spectra were baseline corrected
with a sixth-order polynomial and ﬁrst-order phase-cor-
rected. Curve ﬁtting to the metabolic peaks was applied
using Gaussian or Lorentzian line shapes at known fre-
quencies. Relative metabolite concentrations for N-acetyl
groups (NAA), choline-containing compounds (Cho),
creatine and phosphocreatine (Cre), and glutamate plus
glutamine (Glu ? Gln) were determined, and the metabolic
ratios NAA/Cre, NAA/Cho, Cho/Cre, and (Glu ? Gln)/Cre
were calculated. A model MRS spectrum from one subject is
presented in Fig. 2.
VLMT
Cognitive performance was measured using the German
version of the Rey Auditory Verbal Learning Test (Verbal
Learning Memory Test, VLMT, [35]). The VLMT is a
widely used neuropsychological test of verbal learning and
memory with only minor requirement of language and
Table 2 Clinical data and symptom ratings of the patient groups: data are presented as mean ± standard deviation unless otherwise indicated
Val/val Val/met Met/met Statistics
N Mean SD N Mean SD N Mean SD df F P
Schizophrenia patients (MRS)
CPZ (daily dosage) 20 398.0 387.9 12 204.2 143.7 1, 30 2.74 0.11
CPZ (cumulative) 20 11,241 18,767 12 3,638 3,216 1, 30 1.91 0.18
Duration of psychosis (weeks) 20 45 62 12 46 39 1, 30 0.00 0.98
PANSS positive 20 21.5 5.5 12 22.0 6.2 1, 30 0.07 0.79
PANSS negative 20 23.2 6.6 12 19.8 7.3 1, 30 1.74 0.20
PANSS general 20 49.2 8.8 12 43.1 8.8 1, 30 3.62 0.067
PANSS total 20 93.8 15.6 12 84.9 17.6 1, 30 2.22 0.15
MADRS total score 19 20.1 6.2 11 15.5 5.1 1, 28 4.31 0.047
Bipolar patients (MRS)
Disease duration (years) 16 13.3 10.1 15 13.9 12.0 1 37.0 2, 29 2.17 0.13
MADRS total score 15 4.1 3.4 15 4.6 3.1 1 2.0 2, 28 0.33 0.72
YMRS 14 2.3 3.1 15 3.2 2.7 1 0.0 2, 27 0.81 0.46
Psychotic symptoms (no/yes) 11/5 12/3 1/0 2 0.87 0.65
Neuroleptics (none/FG/SG) 9/1/6 7/2/6 1/0/0 4 1.47 0.83
Lithium (no/yes) 10/6 10/5 0/1 2 1.78 0.41
Other mood stabilizer (no/yes) 4/12 4/11 0/1 2 0.36 0.84
Benzodiazepine (no/yes) 12/3/1 13/2/0 1/0/0 4 1.48 0.83
Antidepressants (no/yes) 13/3 8/7 1/0 2 3.28 0.19
Values are expressed as v
2 statistics for categorical variables and F statistics for continuous variables. N group size, SD standard deviation, df
degrees of freedom, FFstatistic, P error probability of ﬁrst kind, CPZ chlorpromazine equivalent dose, PANSS positive and negative syndrome
scale, MADRS Montgomery-Asberg depression rating scale, YMRS young mania rating scale, FG ﬁrst-generation antipsychotic drugs, and SG
second-generation antipsychotic drugs
Fig. 1 Magnetic resonance
imaging (MRI) demonstrating
the localization and well-
adapted shape of the volume of
interest (voxel size
10 9 35 9 10 mm
3) placed in
the left hippocampus (MR
images in radiological
convention) in a transversal,
b coronal, and c sagittal
orientation
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123motor skills. This test allows the assessment of verbal
declarative memory and investigates the encoding capac-
ity, the direct and delayed recall performance and episodic
recognition abilities [24].
Genotyping
DNA was extracted according to the salting out procedure
[32]. The following primers were used in the polymerase
chain reaction (PCR): 50-AAAGCCCTAACCAGTTTTCT
G-30 (forward) and 50-TCCTCCAGCAGAAAGAGAAG-30
(reverse). The PCR was done in a 50 ll reaction mixture
containing 100 ng of genomic DNA, 200 lM of each
dNTPs, 10 pmol of each primer, 0.5 units Taq-polymerase,
and buffer (KCl 50 mM, Tris–HCl 10 mM, Tween 20
0.025%, BSA 0.025 mg/ml, and 2.0 mM MgCl2). The
PCR reaction had an initial temperature of 94C( 5m i n )
followed by 35 cycles of denaturation (94C, 45 s),
annealing (58C, 45 s), and extension (72C, 45 s). An
extension period of 7 min at 72C followed the ﬁnal
cycle. The PCRs were done using an ABI Gene-
Amp
9700 cycler.
PCR products were digested at 37C using Pml1 (NEB,
Ipswich, MA, USA), separated on 2.0% agarose gels
(ROTI
GAROSE NEEO, Roth, Karlsruhe), and genotyped
according to the resulting fragment lengths. BDNF geno-
types were called by two individuals being blind to the
clinical data.
Statistics
For statistical analyses, SPSS for Windows 16.0 was used.
Level of signiﬁcance was set at a\0.05. All tests were
two-tailed. Only in cases in which analyses were based on
a priori hypotheses derived from literature (e.g., [10, 41]),
results are presented without correction of error probabil-
ities for multiple testing (see also [41]).
In order to determine possible confounding variables,
effects of age and duration of education on the dependent
variables were assessed within the sample of healthy con-
trols using Pearson product moment correlations, while
one-way analysis of variance (ANOVA) was performed to
examine the inﬂuence of the factors gender and handedness
as well as (in the entire sample) of the factor diagnosis. For
further analysis, the intervening variables education, age,
gender, and diagnosis were included into the MANCOVA,
as each of these intervening variables had a signiﬁcant
inﬂuence on some of the dependent variables.
Subjects of the three different groups (schizophrenia,
bipolar I, and healthy controls) were separated according to
the BDNF genotype into homozygous carriers of the val-
allele (val/val) or the met-allele (met/met), and heterozy-
gotes (val/met). These genotype groups were compared to
each other with regard to the dependent variables (i) rela-
tive hippocampal volumes (left and right), (ii) MRS ratios
in the left hippocampus, and (iii) overall performance in
the verbal learning memory test. For (i) a repeated mea-
sures MANCOVA with between-subject factors BDNF
genotype, gender and diagnosis, within-subject factor side
and covariates age and education was calculated. For (ii)
MANCOVA and for (iii) ANCOVA with factor BDNF
genotype and the intervening variables education, age,
gender, and diagnosis were performed. In case of signiﬁ-
cant effects for the factor BDNF genotype in the MAN-
COVA, we performed post-hoc comparisons between
groups in order to further evaluate the genetic effect. In
particular, to evaluate the effects of only one met-allele,
val/met heterozygotes were compared with val homozy-
gotes (val/val). In order to address the effect of two met-
alleles, met homozygotes (met/met) were compared with
val homozygotes (val/val).
To make our results more comparable to other studies,
we calculated the effect sizes for the results of the ANOVA
(f values).
Results
The frequency of the BDNF val/val genotype in the overall
sample was 65% in schizophrenia patients and 54% in
patients with bipolar I disorder, and 57% in healthy sub-
jects, which is in accordance with previously published
Fig. 2 Typical proton magnetic resonance spectroscopy spectrum
(1H-MRS) from the left hippocampus
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123data. Overall, the genotype frequencies were in the Hardy–
Weinberg equilibrium (P = 0.93).
BDNF effects on hippocampal volumes
The inter-rater reliability (intraclass correlation coefﬁ-
cient = ICC) and the intra-rater reliability for the volu-
metric hippocampal measurement was 0.93 and 0.99,
respectively. Repeated measures MANCOVA did not
reveal any signiﬁcant effect of the BDNF val66met poly-
morphism on relative hippocampal volume (F(2,
86) = 0.50, P = 0.61). Furthermore, MANCOVA did
neither reveal a signiﬁcant interaction side x BDNF nor
diagnosis x BDNF.
BDNF effects on magnetic resonance spectroscopy
markers in hippocampus, dorsolateral prefrontal,
and frontomedian cortex
Initial MANCOVA (factor: BDNF, intervening variables
education, age, gender, and diagnosis) showed a signiﬁcant
effect of BDNF val66met genotype on MRS ratios in the
left hippocampus (F(10, 162) = 1.91, P = 0.048, effect
size: f = 0.342), but not in the left dorsolateral prefrontal
cortex (F(10, 176) = 0.91, P = 0.52) nor in the left pos-
terior frontomedian cortex (F(10, 176) = 0.65, P = 0.77).
For all the three regions, the interaction diagnosis x BDNF
was not signiﬁcant.
Post-hoc comparisons for BDNF genotype effects on
MRS markers in the left hippocampus revealed that
met/met homozygotes had signiﬁcantly lower NAA/Cre
(-21.1%; F(1, 52) = 4.80, P = 0.033, effect size:
f = 0.303 and (Glu ? Gln)/Cre (-46.0%; F(1, 52) = 6.20,
P = 0.016, effect size: f = 0.346) ratios as compared with
val/val homozygotes (Fig. 3a, b), while the difference in
the NAA/Cho ratio did not reach the level of signiﬁcance
(-15.1%; F(1, 52) = 1.78, P = 0.185). Mean values of
these MRS ratios in the heterozygous val/met group gen-
erally laid in between the two homozygous groups. How-
ever, no statistically signiﬁcant effect for a reduction in the
MRS ratios in the val/met group as compared with the val/
val homozygotes could be observed.
When all met-allele carriers (homozygotes and hetero-
zygotes) were pooled and contrasted with val/val homo-
zygotes, no signiﬁcant differences in MRS ratios could be
detected. The interaction diagnosis 9 BDNF did not show
a signiﬁcant effect.
BDNF effects on verbal memory
Consistent with previous studies on verbal memory, carri-
ers of the met-allele numerically revealed a reduced overall
performance (sum of ﬁve direct recalls) in the verbal
learning memory test, but this did not turn out to be sta-
tistically signiﬁcant in the ANCOVA (F(2, 98) = 0.30,
P = 0.74, effect size: f\0.1).
Discussion
In the present study, we investigated the impact of the
functional BDNF val66met polymorphism on magnetic
resonance spectroscopic markers (NAA/Cre, NAA/Cho,
Cho/Cre, and (Glu ? Gln)/Cre) in the left hippocampus,
left dorsolateral prefrontal, and left posterior frontomedian
cortex, as well as on hippocampal volumes and on verbal
memory capacity in a group of 158 subjects (66 schizo-
phrenia patients, 45 BD patients, and 47 healthy controls).
Our main ﬁnding was a signiﬁcant effect of BDNF
genotype on metabolic markers speciﬁcally in the left
hippocampus. In particular, homozygous carriers of the
Fig. 3 Signiﬁcant effects of the functional BDNF val66met polymor-
phism rs6265 on magnetic resonance spectroscopic markers (a NAA/
Cre;b (Glu ? Gln)/Cre) in the lefthippocampus.*P\0.05. The y-axis
represents the ratios between NAA/Cre and (Glu ? Gln)/Cre
28 Eur Arch Psychiatry Clin Neurosci (2012) 262:23–31
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(Glu ? Gln)/Cre metabolic ratios as compared with val/val
homozygotes (Fig. 3). This effect was conﬁrmed by con-
trolling for identiﬁed intervening covariates. Although in
the heterozygous val/met group, the mean values of these
MRS ratios laid in between the two homozygous groups,
no signiﬁcant effect of the presence of only one met-allele
could be detected in this group. Thus, our data suggest that
BDNF effects on NAA/Cre and (Glu ? Gln)/Cre ratios in
the left hippocampus may be speciﬁc for (or at least most
pronounced in) homozygous carriers of the met-allele.
Alternatively, these effects may be present in heterozygotes
for the met-allele as well, but may be too small to have
reached the level of statistical signiﬁcance in our sample.
Overall, these MRS results are consistent with previous
reports of a signiﬁcant reduction in left hippocampal NAA/
Cre and NAA/Cho levels in carriers of the BDNF rs6265
met-allele [10, 41]. Thus, we were able to replicate these
prior ﬁndings in an ethnically homogeneous sample of only
caucasians. Furthermore, our data that were acquired in a
mixed sample of both healthy subjects and psychiatric
patients with psychotic disorders suggest that the observed
BDNF genotype effects on MRS markers may be relatively
independent of these psychiatric diagnoses as there were no
effects of diagnosis on these markers and no genotype x
diagnosis interactions. Moreover, our ﬁndings provide in
vivo evidence for an effect of the functional BDNF poly-
morphism on glutamate levels in the left human hippo-
campus, which is consistent with the theory that BDNF
may impact NAA via its inﬂuence on the glutamate system
[6, 41].
Our negative MRS ﬁnding in the posterior frontomedian
cortex seems to contradict the very recent observation of
higher NAA levels in the anterior cingulate cortex of met-
allele carriers [13]. The authors interpreted this ﬁnding
tentatively as an up-regulation of cingulate NAA to com-
pensate decreasing hippocampal NAA in met-allele carri-
ers. Several methodological differences may account for
these partially discrepant results, such as the precise
placement and the size of MRS voxels, the measurement of
absolute versus relative metabolite concentrations and
numerical as well as genetic differences between samples.
For example, it is unclear whether and to what extent the
rather large ACC voxel recorded by Gallinat and col-
leagues overlaps with our voxel in the posterior fronto-
median cortex, which was anatomically precisely deﬁned
as (and adjusted to) the (left sided) cingulate cortex located
dorsally and posterior to the genu of the corpus callosum
along the cingulate sulcus (see [23], for a very similar
voxel positioning, however, centered on the interhemi-
spheric ﬁssure). Functionally, this cortical region has been
implicated in adaptive cognitive control of behavior, in
particular in background monitoring of the environment for
potentially signiﬁcant sensory events [15]. Given the fact
that BDNF effects on MRS markers appear to be region-
ally speciﬁc (as indicated by the present and other results),
this highlights the importance of investigating clearly
deﬁned and (presumably) functionally homogeneous brain
regions.
With regard to BDNF effects on brain structure, we
were unable to replicate prior ﬁndings of a hippocampal
volume reduction in carriers of the met-allele [12, 21, 37]
as we did not ﬁnd any effect of BDNF genotype on hip-
pocampal volume. Thus, this negative ﬁnding is more
consistent with other recent studies which also did not
observe BDNF genotype effects on structural volumes of
the hippocampus [33, 41]. While our ﬁnding further
excludes that the observed BDNF effects on MRS markers
might have resulted from confounding differences in hip-
pocampus volume (see [41]), it is still possible that BDNF
may also impact on hippocampal structure, but with lower
effect size, which may not be observable in diagnostically
heterogeneous samples. Furthermore, the results are com-
patible with the suggestion that neurochemical MRS
markers may be more sensitive to BDNF genotype effects
than volumetric measures [41]. Interestingly, one study
showed that the BDNF val66met polymorphism is associ-
ated with temporal gray matter loss over 4 years in patients
with Bipolar I Disorder [31]. Hence, it is possible that
BDNF effects on brain structure may only be observable in
longitudinal studies that assess changes in the course of
brain disorders. However, in this context, it is worth to
mention that schizophrenia and bipolar affective disorder
share in parts a common pathophysiological pathway and
display similar symptoms, but differ in the disease course
and in the cortical gray matter loss [9, 34].
Finally, our ﬁnding of a numerical, but nonsigniﬁcant
effect of BDNF genotype on verbal memory is quite con-
sistent with previous reports of BDNF genotype effects on
episodic memory and, to a lesser extent, on verbal memory
[5, 10, 16]. As verbal memory tests like the California
Verbal Learning Test (CVLT) and the Verbal Learning
Memory Test (VLMT) may (in comparison to episodic
memory tests) also impose considerable demands on pre-
frontal cortical functions, this may explain the lack of
statistical signiﬁcance for BDNF effects on the VLMT in
the present study (for a similar discussion see Egan et al.
2003). Given the fact that BDNF is well-known to facilitate
LTP, i.e., memory-related processes in the hippocampus [1,
5, 8, 10, 12, 21, 22, 36–38], further studies are deﬁnitely
required to clarify possible effects of BDNF genotype on
hippocampus-dependent cognition. A possible bias of these
results might be the effects of concomitant medication on
cerebral neurochemistry. This phenomenon is being con-
troversially disputed by different authors, and there might
be an effect of neuroleptics on cerebral NAA levels [4, 11,
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12318], although in the light of other studies, this appears to be
unlikely [18, 26].
It can further be speculated whether our results are
linked to the heritability of our outcome measures. Dif-
ferent studies point toward heritability of hippocampal
volumetric measures, hippocampal spectroscopy parame-
ters, and of verbal memory [20, 25, 30]. Our ﬁnding of a
BDNF effect in a mixed sample of healthy controls and
patients suffering from schizophrenia and BP is indeed
compatible with the assumption of heritability of our out-
come parameters.
In summary, the present ﬁndings provide further evi-
dence for a crucial role of BDNF in hippocampal func-
tioning. In this context, BDNF has been linked to
hippocampus-related forms of learning and memory, in
particular via its effects on activity-dependent changes in
synaptic strength of glutamatergic synapses [3]. BDNF has
been shown both to facilitate glutamate release at the
presynapse and to increase postsynaptic glutamate receptor
phosphorylation and synthesis [6]. In consideration of these
ﬁndings, only recently, it had been hypothesized that
BDNF may exert its observed effects on NAA via its
inﬂuence on the glutamatergic system [41]. Consistent with
this hypothesis, the present results provide ﬁrst in vivo
evidence for an effect of the functional BDNF val66met
polymorphism on the glutamate system in human hippo-
campus. Furthermore, our data suggest that these BDNF
effects on NAA and glutamate in the hippocampus may be
most pronounced in homozygous carriers of the BDNF
met-allele.
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